
Biogen to Acquire Apellis, Expanding Immunology and Rare Disease Portfolio and Entering Nephrology
Biogen’s Acquisition of Apellis Strengthens Immunology and Rare Disease Portfolio While Accelerating Growth and Entry into Nephrology Biogen Inc. and Apellis Pharmaceuticals (Nasdaq: APLS) have announced a definitive agreement under…












